Literature DB >> 10514409

Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor.

A Chott1, Z Sun, D Morganstern, J Pan, T Li, M Susani, I Mosberger, M P Upton, G J Bubley, S P Balk.   

Abstract

An important biological feature of prostate cancer (PCa) is its marked preference for bone marrow as a metastatic site. To identify factors that may support the growth of PCa in bone marrow, expression of receptor and nonreceptor tyrosine kinases by androgen-independent PCa bone marrow metastases was assessed. Bone marrow biopsies largely replaced by PCa were analyzed using reverse transcriptase-polymerase chain reaction amplification with degenerate primers that amplified the conserved kinase domain. Sequence analyses of the cloned products demonstrated expression of multiple kinases. Expression of the receptor and nonreceptor tyrosine kinases, alpha platelet-derived growth factor receptor and Jak 1, respectively, was confirmed by immunohistochemistry. In contrast, the type 1 insulin-like growth factor receptor, thought to play a role in PCa development, was lost in metastatic PCa. These results implicate several specific growth factors and signaling pathways in metastatic androgen-independent PCa and indicate that loss of the type 1 insulin-like growth factor receptor contributes to PCa progression.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514409      PMCID: PMC1867033          DOI: 10.1016/S0002-9440(10)65229-7

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Cloning members of protein-tyrosine kinase family using polymerase chain reaction.

Authors:  A F Wilks
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow.

Authors:  M Chackal-Roy; C Niemeyer; M Moore; B R Zetter
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

3.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.

Authors:  M E Taplin; G J Bubley; Y J Ko; E J Small; M Upton; B Rajeshkumar; S P Balk
Journal:  Cancer Res       Date:  1999-06-01       Impact factor: 12.701

4.  Selective stimulation of prostatic carcinoma cell proliferation by transferrin.

Authors:  M C Rossi; B R Zetter
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

Review 5.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens.

Authors:  J Veldscholte; C A Berrevoets; C Ris-Stalpers; G G Kuiper; G Jenster; J Trapman; A O Brinkmann; E Mulder
Journal:  J Steroid Biochem Mol Biol       Date:  1992-03       Impact factor: 4.292

6.  Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

Authors:  M Gleave; J T Hsieh; C A Gao; A C von Eschenbach; L W Chung
Journal:  Cancer Res       Date:  1991-07-15       Impact factor: 12.701

7.  Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.

Authors:  M E Gleave; J T Hsieh; A C von Eschenbach; L W Chung
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

8.  Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells.

Authors:  M Haq; D Goltzman; G Tremblay; P Brodt
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

9.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

10.  Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin.

Authors:  G Yan; Y Fukabori; S Nikolaropoulos; F Wang; W L McKeehan
Journal:  Mol Endocrinol       Date:  1992-12
View more
  46 in total

1.  Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.

Authors:  Gary E Gallick; Paul G Corn; Amado J Zurita; Sue-Hwa Lin
Journal:  Future Med Chem       Date:  2012-01       Impact factor: 3.808

Review 2.  Progress of molecular targeted therapies for prostate cancers.

Authors:  Weihua Fu; Elena Madan; Marla Yee; Hongtao Zhang
Journal:  Biochim Biophys Acta       Date:  2011-11-29

3.  Progression to metastatic stage in a cellular model of prostate cancer is associated with methylation of the androgen receptor gene and transcriptional suppression of the insulin-like growth factor-I receptor gene.

Authors:  Hagit Schayek; Itay Bentov; Shihua Sun; Stephen R Plymate; Haim Werner
Journal:  Exp Cell Res       Date:  2010-03-23       Impact factor: 3.905

4.  A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer.

Authors:  Carolyn V Ustach; Wei Huang; M Katie Conley-LaComb; Chen-Yong Lin; Mingxin Che; Judith Abrams; Hyeong-Reh Choi Kim
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

5.  Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer.

Authors:  Ju-Won Roh; Jie Huang; Wei Hu; XiaoYun Yang; Nicholas B Jennings; Vasudha Sehgal; Bo Hwa Sohn; Hee Dong Han; Sun Joo Lee; Duangmani Thanapprapasr; Justin Bottsford-Miller; Behrouz Zand; Heather J Dalton; Rebecca A Previs; Ashley N Davis; Koji Matsuo; Ju-Seog Lee; Prahlad Ram; Robert L Coleman; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

6.  The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms.

Authors:  Mike R Russell; Qingxin Liu; Hetian Lei; Andrius Kazlauskas; Alessandro Fatatis
Journal:  Cancer Res       Date:  2010-05-04       Impact factor: 12.701

7.  Expression of the IGF axis is decreased in local prostate cancer but enhanced after benign prostate epithelial differentiation and TGF-β treatment.

Authors:  Petra Massoner; Michael Ladurner Rennau; Isabel Heidegger; Anita Kloss-Brandstätter; Monika Summerer; Eva Reichhart; Georg Schäfer; Helmut Klocker
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

8.  [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].

Authors:  C-H Ohlmann; E Markert; M Gerharz; D Pfister; H-P Dienes; U Engelmann; A Heidenreich
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

Review 9.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Clara Hwang; Elisabeth I Heath
Journal:  J Hematol Oncol       Date:  2010-08-02       Impact factor: 17.388

10.  Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases.

Authors:  Sen Chen; Xinnong Jiang; Christina A Gewinner; John M Asara; Nicholas I Simon; Changmeng Cai; Lewis C Cantley; Steven P Balk
Journal:  Sci Signal       Date:  2013-05-28       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.